The first prospective trial of sacituzimab govitecan (+ trastuzumab) after T-DXd for HER2+ MBC

Paolo Tarantino shared a post by Dana-Farber’s Breast Oncology Center on X, adding:

“There’s few open questions as critical in oncology as ADC sequencing We’re trying to answer it with SATEEN. The first prospective trial of sacituzimab govitecan (+ trastuzumab) after T-DXd for HER2+ MBC.

Currently enrolling at Dana-Farber’s Breast Oncology Center.”

Quoting Dana-Farber’s Breast Oncology Center:

“The SATEEN trial, led by Dana-Farber’s Breast Oncology Center, is a multi-center, single-arm phase II trial evaluating the safety and effectiveness of sacituzumab govitecan with trastuzumab for HER2+ Metastatic Breast Cancer. For more information call 877-338-7425 or visit.”

Source: Paolo Tarantino/X and Dana-Farber’s Breast Oncology Center/X

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.